Effectiveness of Montelukast in Reducing the Risk of Severe Dengue in Dengue Fever Patients: An Evidence-Based Case Report
- Author:
Nicholas Jason Wijaya
1
;
Sharifah Shakinah
2
;
Leonard Nainggolan
2
;
Erni Juwita Nelwan
2
Author Information
- Publication Type:Journal Article
- Keywords: evidence-based case report; severe dengue; dengue fever; leukotriene receptor antagonist; montelukast
- MeSH: evidence-based case report; severe dengue; dengue fever; leukotriene receptor antagonist; montelukast
- From: Acta Medica Indonesiana 2026;58(1):115-122
- CountryIndonesia
- Language:English
- Abstract: Abstract:Background: Dengue fever continues to spread worldwide, particularly in tropical regions. Some patients with dengue fever may progress to severe dengue, which is associated with significantly higher morbidity and mortality. Despite this, no definitive treatment has been found to prevent its progression. Montelukast, a leukotriene receptor antagonist, has shown potential in reducing plasma leakage, a key factor in the pathophysiology of severe dengue. Therefore, this study aimed to evaluate the effectiveness of montelukast in reducing the risk of severe dengue. Methods: A systematic literature search was conducted on April 16, 2025, using keywords related to montelukast and dengue across four databases, which included PubMed, Taylor and Francis, Cochrane Library, and ScienceDirect. A critical appraisal was performed using the Oxford Centre for Evidence-Based Medicine framework, evaluating the validity, importance, and applicability of each study. The primary outcomes were the incidence of dengue shock syndrome and dengue with warning signs. The secondary outcomes included mortality rate and hospitalization duration. Results: This study included three studies involving a total of 1057 patients. Montelukast is associated with a reduced incidence of dengue shock syndrome and shorter duration of hospitalization. However, the effect of montelukast on dengue with warning signs and mortality rate was inconclusive. Conclusion: Montelukast shows potential as an adjuvant therapy in preventing the progression of dengue fever to severe dengue. However, further research is required before montelukast can be widely recommended for dengue fever patients in daily clinical practice and possibly integrated into dengue fever clinical guidelines.
- Full text:202606291642235585sa-Nicholas Jason Wijaya.pdf
